Pricing Log in Create free account

GT Biopharma, Inc. (GTBP) vs Moleculin Biotech, Inc. (MBRX)

GT Biopharma, Inc. and Moleculin Biotech, Inc. are both Biotechnology companies. GT Biopharma, Inc. and Moleculin Biotech, Inc. are of similar size ($9.4M and $9.2M). Moleculin Biotech, Inc. trades at the lower P/E: 0.0× against 0.8×. Across the 11 metrics below, Moleculin Biotech, Inc. leads on 6 and GT Biopharma, Inc. on 5.

Valuation

Metric GTBP MBRX Biotechnology median
P/E 0.76 0.04 10.60
P/S 114.39 n/m 9.40
P/B 1.92 0.22 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.16 0.66
EV/Sales 475.21 n/m 9.02
Earnings yield 130.83% 2,530.42% (32.88%)
Free cash flow yield (207.77%) (1,010.33%) (23.13%)

Profitability

Metric GTBP MBRX Biotechnology median
Gross margin 41.67% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 102.03% (1,471.05%) (51.96%)
Return on assets (176.27%) (152.41%) (46.06%)
Return on invested capital 0.00% (417.27%) 0.00%

Growth

Metric GTBP MBRX Biotechnology median
Revenue growth (TTM) (76.19%) — 6.76%
EPS growth (last fiscal year) 3.75% 82.01% 29.88%
Revenue growth, 5-year CAGR 19.67% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GTBP MBRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.61 0.94 4.97
Net debt to EBITDA 0.56 0.35 1.01

Dividend

Metric GTBP MBRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GTBP MBRX Biotechnology median
Market cap 9.36m 9.16m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack